Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ViviGen is a cellular bone matrix (cellular allograft) developed by LifeNet Health and distributed by DePuy Synthes. It is designed to provide a comprehensive solution for bone repair by delivering the three essential components of bone formation: osteoconduction, osteoinduction, and osteogenicity. Unlike traditional allografts, ViviGen contains cryopreserved, viable, lineage-committed bone cells (osteoblasts, osteocytes, and bone lining cells) within a corticocancellous bone scaffold and demineralized bone matrix. This composition allows it to mimic the properties of an autograft, which is considered the gold standard in bone grafting. It is primarily indicated for use in orthopedic and spine fusion procedures, such as lumbar and cervical fusion, as well as for the treatment of non-union fractures and traumatic bone defects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ViviGen (LifeNet Health).